Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Phase III trials are planned to assess combined KRAS G12C inhibition/checkpoint inhibition as first-line therapy
However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.